Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
As juries turn against social media for harming kids, Big Tech's invincibility starts to show cracks- Black Friday streaming deals 2025: Grab the Disney+ Hulu bundle for only $5 and save over 60%
- 3 moms, 3 countries, 1 very familiar problem: Why child care costs still don't add up for families
- The most effective method to Pick a Campervan That Offers Something else for Less
- South African radio presenter among five charged over Russia recruitment plot
- Grass Care Administrations for a Wonderful, Sound Yard
- Yes, NASA's launching Artemis 2 astronauts to the moon on April Fools' Day. It's not a joke.
- One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
- Audits of 6 Specialty Mixed drinks
